Cenforce is a sildenafil-linked medicine name promoted in India-market product catalogs, notably those of Centurion Laboratories. This is not a single uniform product: the name appears on conventional sildenafil tablets as well as listings carrying modifiers such as Professional, Super Active, and D. Those suffixes matter because they can refer to different forms or additional ingredients. A brand-family search result cannot substitute for the composition printed on one specific package.
Centurion-linked listings identify sildenafil tablets marketed as Cenforce 25, 50, 100, 150 and 200 mg, although the reliability of individual catalog descriptions varies. For example, promotional copy alongside a product labeled sildenafil sometimes discusses unrelated conditions. That inconsistency makes it important to separate a listed product specification from unverified seller claims. Unusual strengths or purported rapid-release versions should not be treated as U.S.-approved Viagra presentations.
For U.S. readers, the distinction is between an India-market brand and FDA-approved sildenafil ED products. This page catalogs documented Cenforce names and limits of the available evidence; it does not facilitate foreign ordering or imply FDA authorization. For the wider family use Indian sildenafil brands; for products approved for U.S. prescribing use generic sildenafil or Viagra.
The most concrete starting point is a specific listing, not the broad promise that Cenforce is “generic Viagra.” Centurion-linked catalogs name ordinary tablets in several strengths and give separate listings for nonstandard forms. The rows below report what those catalogs claim; they do not independently establish batch authenticity, current legal marketing authorization or availability.
The existence of 150 mg and 200 mg listings is especially important for U.S. readers: the U.S. Viagra ED product line is labeled at 25, 50 and 100 mg. A foreign-marketed higher-strength tablet is not a U.S. prescribing recommendation or evidence of greater benefit.
| Listed product | Claimed identity / form | Evidence and interpretation |
|---|---|---|
| Cenforce 25 / 50 | Sildenafil oral tablets | Centurion-linked product listings; individual pack and company role require confirmation |
| Cenforce 100 | Sildenafil 100 mg tablet | Named in related catalog entries; not an FDA approval record |
| Cenforce 150 | Sildenafil 150 mg tablet | Company-linked listing; outside the labeled Viagra ED strengths |
| Cenforce 200 | Sildenafil 200 mg tablet | Company-linked listing; do not translate into U.S. dose guidance |
| Cenforce Professional | Advertised sublingual sildenafil tablet | Distinct claimed dosage form; clinical and regulatory equivalence not established |
| Cenforce Super Active | Advertised capsule form | A separate presentation, not interchangeable with a conventional tablet by name |
| Cenforce D / D Extra Power | Some listings describe sildenafil plus dapoxetine | Composition needs pack-specific confirmation; not plain sildenafil |
Centurion Laboratories Private Limited has company-linked catalogs that advertise Cenforce sildenafil products. This connects the brand family to a named Indian business more specifically than an anonymous export marketplace does. Several entries attribute manufacturing to Centurion, yet a catalog listing alone does not verify the facility, finished product authorization, batch history or contractual roles for every Cenforce-named item.
A medicine box may distinguish a manufacturer, marketer, exporter and distributor. Preserve those exact roles when comparing two packs. If a reseller claims a different manufacturer or uses mismatched images, the correct conclusion is that product identity is unresolved—not that every Cenforce product is manufactured at one confirmed site.
Cenforce Professional is described in Centurion-linked listings as a sildenafil sublingual tablet, while Super Active appears under capsules. These descriptions are materially different from an ordinary swallowed tablet, even where the intended active ingredient is sildenafil. The words “professional,” “active” or “soft” are branding terms, not independent evidence of faster onset, superior absorption or a safer regimen.
The D naming family raises a different issue. At least one D Extra Power company listing specifies sildenafil combined with dapoxetine. The full ingredients of another similarly named product should never be assumed from the suffix alone. A combination product requires its own safety and regulatory assessment and is not interchangeable with sildenafil-only treatment.
Some Centurion-linked product pages identify sildenafil correctly in their structured specifications yet contain promotional paragraphs referring to unrelated diseases or different product names. This is a concrete sign that template sales copy should not be used as clinical evidence. It does not by itself prove the listed medicine is counterfeit; it does mean the supporting description is insufficient to establish medical claims.
For this page, ingredient, dosage-form and company fields are reported as catalog claims only. Claimed advantages such as immediate response, guaranteed performance and absence of side effects are intentionally excluded. A credible independent product evaluation would need coherent pack labeling and appropriate authorization records.
A Cenforce package mentioning 150 or 200 mg should not be confused with an FDA-approved U.S. Viagra tablet. Strength is only one product characteristic: authorization depends on formulation, route, application holder, labeling and quality evidence. An exporter describing a medicine as “pharmaceutical grade” does not resolve those issues.
The separate U.S. sildenafil strengths guide identifies ED tablet presentations, while the dosage guide covers clinician-directed dose selection. Neither provides a basis to convert a foreign-market strength into a self-directed regimen or take multiple PDE5 inhibitors.
A useful product record gives the full trade name, ingredient expressed as the active amount, dosage form, labeled strength, batch details, marketer and manufacturer. With Cenforce, the modifier after the base brand name may be critical. A seller image showing only “Cenforce” but omitting a suffix cannot establish which of several listed presentations is being offered.
Compare the product identity in a company-linked record with the actual labeling; do not rely on a seller’s picture as proof of authenticity. Missing or contradictory ingredient information is a reason not to assume a specific medicine has been identified.
FDA approval is tied to a specific application and product, not to the sildenafil molecule in every country. Centurion-linked Cenforce listings do not demonstrate an approved U.S. Cenforce ED drug. FDA-approved sildenafil products exist under separately identified brand and generic applications; importing their approval status into a Cenforce description would be misleading.
A U.S. reader comparing active ingredients can use the approved-generic guide for the U.S. regulatory category. Therapeutic-equivalence claims require the actual approved applications; a foreign tablet should not be called an FDA-equivalent generic merely because its listing names sildenafil.
If a particular Cenforce product contains sildenafil, contraindications associated with sildenafil still matter, notably organic nitrates and riociguat. Other cardiovascular drugs, alpha-blockers and some interacting medicines warrant individualized medical review. A D-labelled combination may introduce additional risks from a second ingredient that cannot be evaluated by reading sildenafil instructions alone.
Serious symptoms, including an erection persisting longer than four hours or sudden hearing or vision loss, need urgent medical attention. For the core ingredient warnings see sildenafil and nitrates and sildenafil side effects.
Listings that advertise overseas shipment should not be presented as licensed U.S. pharmacy access. FDA rules generally prohibit importing unapproved prescription medicines, subject only to narrow enforcement-discretion circumstances; an advertised tracking number or prescription-free checkout does not change product authorization.
For legitimate U.S. care, a clinician assesses the patient and a licensed pharmacy dispenses a prescribed, approved medicine. The U.S. sildenafil access guide and the pharmacy-verification guide explain those routes without endorsing a Cenforce import seller.
Unlike a single U.S. brand-and-generic comparison, these foreign-market brands are connected to different company catalogs and naming systems. Cenforce has notably broad Centurion-linked listings, including unusually high strengths and suffixes associated with sublingual, capsule and combination products. That specificity is the reason this page exists separately from Fildena and Kamagra.
A useful cross-brand comparison asks whether the individual product is sildenafil-only and what dosage form is documented; it does not rank these brands by strength or promise more reliable effects. The Indian-brand directory provides a consistent index, while this page is dedicated to Cenforce product evidence.
No. Centurion-linked catalogs use Cenforce for several tablet strengths and also list Professional, Super Active and D-named variants with different claimed characteristics.
Company-linked catalogs describe 25, 50, 100, 150 and 200 mg sildenafil tablet products. These are listing claims, not approval of those strengths in the United States.
It is advertised as a sublingual product. That claimed form is distinct from a standard swallowed tablet and should not be assumed therapeutically equivalent.
Some Cenforce D-related listings describe sildenafil with dapoxetine. The ingredients of a specific D-named pack must be confirmed rather than inferred.
Centurion-linked catalogs advertise multiple Cenforce medicines and attribute products to the company; that does not independently authenticate every item marketed under the name.
Certain catalog pages mix sildenafil specifications with unrelated promotional text. Such prose is insufficient for clinical or regulatory conclusions.
The foreign-market brand listings do not establish an FDA-approved Cenforce application. U.S.-approved Viagra and sildenafil generics are separate products.
A foreign seller listing is not a lawful substitute for a prescription filled by a licensed U.S. pharmacy; unapproved importation is generally prohibited.